<?xml version="1.0" encoding="UTF-8"?>
<p id="p0015">Based on the pathophysiology of SARS-CoV-2 infection and pleiotropic effects of ACE inhibitors (ACEâ€”Is)/angiotensin receptor blockers (ARBs), these agents may have a potential role in the management of select patients with severe COVID-19. Studies to fill important knowledge gaps in human participants regarding the basic science of ACE2, COVID-19 serology and outcomes are clearly needed.</p>
